• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antipsychotic Updates

Antipsychotic Updates

February 1, 2004
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.

Tired of industry-funded antipsychotic trials? The NIMH comes to the rescue with the "CATIE" project (Clinical Antipsychotic Trials of Intervention Effectiveness). Blissfully un-industry-funded researchers have enrolled 1500 schizophrenic patients at 50 different sites, and have randomly assigned them to Zyprexa, Seroquel, Risperdal, Geodon, or Trilafon (perphenazine). This will allow us to compare the effectiveness of different atypicals, and will also evaluate whether atypicals are truly better than conventionals. The first results are due in a year or so; Big Pharma is holding its breath.

The Zyprexa juggernaut rolls on. A psychopharmacologic overachiever, it excels at everything, with a new FDA indication for maintenance treatment of bipolar disorder as well as treatment of acute mania....Meanwhile, Symbyax, a combination of Zyprexa and Prozac, was just approved for the treatment of bipolar depression. It's supplied as 6/25 (6 mg Zyprexa/25 mg Prozac), 6/50, 12/25, and 12/50 capsules. The mean dose used in the major published trial was 7 mg Zyprexa and 40 mg Prozac (Arch Gen Psychiatry 2003;60:1079). The 8 week 48% remission rate was twice that of placebo, but Symbyax also outperformed placebo in those typically unpleasant Zyprexoid ways--weight gain (20% of patients gained significant weight) and metabolic havoc (a 10 point increase in cholesterol and a 6 point increase in random blood glucose).

Risperdal Consta is getting rave reviews in the field. It's the first atypical depot neuroleptic. Dose it at 25 mg to 50 mg IM Q 2 weeks. Especially at the 25 mg dose, EPS are no different from placebo and weight gain is negligible (Am J Psychiatry 2003;160:1125). No more shaky, shuffling Haldol decanoate-niks.

Good old oral Risperdal got a big boost recently from "The Expert Consensus Guideline Series" published by The Journal of Clinical Psychiatry (2003, vol. 16, suppl 12). Risperdal was voted the "treatment of choice" for both first-episode patients and multiepisode patients. Of course, Janssen Pharmaceutica paid for the survey and the supplement, and they got good opinions for their cash.

Seroquel is causing so many people to sleep for so many hours that savvy psychopharmacologists are reserving it for the seriously over-stimulated insomniac patient group. Keep it at HS, and warn your patients of that "knocked off your feet" kind of feeling. To be fair, tolerance develops after a week or two, and the risk of akathisia on Seroquel is practically nil.

Geodon is being used increasingly as a first line agent even though the Mount Sinai Conference Schizophrenia experts say it should only be used second line (Schiz Bull 2002;28:5). Basically, with no verified cases of torsade de pointes yet reported in post-marketing surveillance, clinicians are feeling more comfortable prescribing it, as long as they have their list of contraindicated agents at their side (see Geodon Fact Sheet in www.thecarlatreport. com).

Nonetheless, Pfizer had its hand slapped by the FDA in September of 2002 because of "misleading" promotional material. The journal ads implied that Geodon does not cause torsade; the FDA countered that post-marketing experience hasn't been sufficient to definitively rule out Geodon's role in causing several reported cases of sudden death....When using Geodon for psychosis, experts have found that higher doses are necessary, and that sedation is a common limiting side effect. Start at 40 mg BID for one or two days, then bump up to 40 mg AM/80 mg HS, and you may need to ratchet up to the FDA max of 160 mg QD (40/120)...Also, look for an FDA bipolar mania indication soon; Pfizer submitted impressive efficacy data in October 2003.

Abilify (see TCR 1:2) is one of the more stimulating antipsychotics and should not be given at night. Start at 5 mg QAM for the first day or two (BMS just introduced a 5 mg tablet), primarily to minimize nausea and insomnia, and then bump it up to 10 to 20 mg QAM. Most patients will need a dusting of trazodone or Ambien as an adjunct. It and Geodon are still the cleanest in terms of weight gain and hyperglycemia.
General Psychiatry
KEYWORDS antipsychotics
    Carlat 150x150
    Daniel Carlat, MD

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    More from this author
    www.thecarlatreport.com
    Issue Date: February 1, 2004
    SUBSCRIBE NOW
    Table Of Contents
    Choosing Atypicals
    Dr. John Buse on Diabetes and Atypicals
    Antipsychotic Updates
    The Diabetes Conundrum
    Efficacy and Atypicals: It’s Hand-to-Hand Combat
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.